Miriam M. Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Miriam M. Hu has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Alison M. Mondul
University of Michigan 28 Ann Arbor, MI
89 shared publications - Bhramar Mukherjee
Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA
89 shared publications - Celeste Leigh Pearce
Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, United States
89 shared publications - Christopher R. Friese
School of Nursing and Rogel Cancer Center, University of Michigan, Ann Arbor, USA
89 shared publications - Lars G. Fritsche
Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, USA
89 shared publications - Lauren J. Beesley
Information Systems & Modeling, Los Alamos National Laboratory
89 shared publications
Latest Publications
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Flowchart describing derivation of COVID-19 tested analytic cohort from raw COVID-19 tested data.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Flowchart describing derivation of COVID-19 tested analytic cohort from raw COVID-19 tested data.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 hospitalization among recent cancer (within three years of positive COVID-19 test; n = 6,143) and non-cancer patients (n = 41,545) who tested positive and have non-missing covariates. The results were from the model logit P(YHospitalization = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 hospitalization among recent cancer (within three years of positive COVID-19 test; n = 6,143) and non-cancer patients (n = 41,545) who tested positive and have non-missing covariates. The results were from the model logit P(YHospitalization = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Logistic regression odds ratios (95% CI) for COVID-19 outcomes by chemotherapy treatment (without hematologic malignancy patients).
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Logistic regression odds ratios (95% CI) for COVID-19 outcomes by chemotherapy treatment (without hematologic malignancy patients).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Severe COVID-19 among cancer (n = 12,995) and non-cancer patients (n = 34,693) who tested positive and had non-missing covariates. The results were from the model logit P(YSevereCOVID = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Severe COVID-19 among cancer (n = 12,995) and non-cancer patients (n = 34,693) who tested positive and had non-missing covariates. The results were from the model logit P(YSevereCOVID = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Logistic regression odds ratios (95% CI) for COVID-19 outcomes by hematologic malignancy type.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Logistic regression odds ratios (95% CI) for COVID-19 outcomes by hematologic malignancy type.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Phecodes used to identify individuals with cancer, along with their phenotype description and the number of individuals in the tested positive cohort with the corresponding phecode.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Phecodes used to identify individuals with cancer, along with their phenotype description and the number of individuals in the tested positive cohort with the corresponding phecode.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
A schematic representing electronic health record scenarios and their resulting (panel A) classification of individuals with cancer for the primary and cancer recency analyses and (panel B) vaccination status for vaccine-related analyses.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
A schematic representing electronic health record scenarios and their resulting (panel A) classification of individuals with cancer for the primary and cancer recency analyses and (panel B) vaccination status for vaccine-related analyses.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 ICU admission among recent cancer (within three years of positive COVID-19 test; n = 6,143) and non-cancer patients (n = 41,545) who tested positive and have non-missing covariates. The results were from the model logit P(YICU = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 ICU admission among recent cancer (within three years of positive COVID-19 test; n = 6,143) and non-cancer patients (n = 41,545) who tested positive and have non-missing covariates. The results were from the model logit P(YICU = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancer + βIntX × Cancer + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 ICU admission among cancer (n = 12,995) and non-cancer patients (n = 34,693) who tested positive and had non-missing covariates. The results were from the model logit P(YICU = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancerStatus + βIntX × CancerStatus + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
COVID-19 ICU admission among cancer (n = 12,995) and non-cancer patients (n = 34,693) who tested positive and had non-missing covariates. The results were from the model logit P(YICU = 1|X, Cancer, Covariate) = β0 + βXX + βCancerCancerStatus + βIntX × CancerStatus + βCovCovariate, where Covariate = Age + Race/Ethnicity + Sex + Disadvantage Index (quartile) + Comorbidity Score. Reference groups were age: 18 to 35, sex: female, BMI: 18.5 to 25, race: white/non-Hispanic, smoking status: never. A unit change in the continuous age variable is 10 years. The comorbidity score ranges from 0 to 6 and is the sum of indicators for presence of six categories of preexisting conditions in the electronic health record.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Phecodes corresponding to the comorbidity classes included in the comorbidity score and their counts in the analytic tested-positive cohort.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from COVID-19 Outcomes by Cancer Status, Site, Treatment, and Vaccination
Phecodes corresponding to the comorbidity classes included in the comorbidity score and their counts in the analytic tested-positive cohort.